Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-Rad ABLTS:0R44 80 EV-to-EBITDA is 13.10 as of Aug. 22, 2026, which is 49% below its 10-year median of 25.60. GuruFocus rates LTS:0R44 with a GF Score™ of 80/100 and a GF Value™ of kr33.58 (Fairly Valued). The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, C-Rad AB ranks better than 53.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, C-Rad AB's enterprise value is kr1,022.0 Mil.
C-Rad AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr78.0 Mil. Therefore, C-Rad AB's EV-to-EBITDA for today is 13.10.
The historical rank and industry rank for C-Rad AB's EV-to-EBITDA or its related term are showing as below:
LTS:0R44'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -219.83 Med: 25.6 Max: 1223.65
Current: 13.12
During the past 13 years, the highest EV-to-EBITDA of C-Rad AB was 1223.65. The lowest was -219.83. And the median was 25.60.
LTS:0R44's EV-to-EBITDA is ranked better than 53.88% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.7
vs LTS:0R44: 13.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
C-Rad AB's share price for today is kr36.00.
C-Rad AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for C-Rad AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R44 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, C-Rad AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where C-Rad AB's EV-to-EBITDA falls into.
C-Rad AB's current Enterprise Value is kr1,022.0 Mil.
C-Rad AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr78.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB (LTS:0R44) has a EV-to-EBITDA of 13.10 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on C-Rad AB. This is 49% below median its historical median of 25.60. According to the industry distribution chart, C-Rad AB ranks #238 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 46.1%.
Is C-Rad AB's EV-to-EBITDA too high?
C-Rad AB's current EV-to-EBITDA of 13.10 is 49% below median its 10-year median of 25.60. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.70. C-Rad AB's value of 13.10 is 10.9% below this industry median. Based on the distribution chart, C-Rad AB ranks #238 out of 516 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, C-Rad AB has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #238 out of 516 companies for EV-to-EBITDA. This puts C-Rad AB in the upper half of its industry. The industry median EV-to-EBITDA is 14.70. C-Rad AB's value of 13.10 is 10.9% below this benchmark. While the company's 10-year median is 25.60 vs. the industry median of 14.70, C-Rad AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.70, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current EV-to-EBITDA of 13.10 is 10.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on C-Rad AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current EV-to-EBITDA is 13.10, which is 49% below median its own 10-year median of 25.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.58, compared to a current price of kr36.00 — trading 7.2% above its estimated fair value. The current EV-to-EBITDA is 13.10, which is 49% below median its 10-year median of 25.60 and 10.9% below the Medical Devices & Instruments industry median of 14.70. C-Rad AB's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current EV-to-EBITDA is 13.10 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr36.00 is trading 7.2% above its estimated GF Value™ of kr33.58.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for LTS:0R44:
EV-to-EBITDA: 13.10 (49% below median its 10-year median of 25.60)
GF Value™: kr33.58 vs. price of kr36.00 (7.2% above fair value)
Industry Position: 10.9% below the Medical Devices & Instruments median (#238 of 516)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
80GF Score
Get the complete analysis for LTS:0R44
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
